Für diesen Artikel ist leider kein Bild verfügbar.

Treatment of High-Risk Early Stage Lung Cancer

Jeffrey Bogart, Frank Detterbeck (Herausgeber)

Buch | Hardcover

2019 | 1st ed. 2019
Springer International Publishing (Verlag)
978-3-319-08538-8 (ISBN)

Titel wird leider nicht erscheinen

Artikel merken

Following very significant advances, it is now widely recognized that definitive treatment should be considered in patients with stage I non-small cell lung cancer (NSCLC) who have pulmonary dysfunction and/or other co-morbidities. This book is a detailed guide to the evaluation and management of these high-risk patients. It first addresses issues such as pathologic considerations, assessment of co-morbidity and the imaging and staging of NSCLC. Surgical and radiotherapy treatment options, including sublobar resection, minimally invasive surgery, brachytherapy, stereotactic body radiotherapy and proton and charged particle therapy, are then discussed in detail. The role of radiofrequency ablation, salvage local therapy and systemic chemotherapy is also considered. Treatment of High-Risk Early Stage Lung Cancer will be of great interest to radiation and medical oncologists, thoracic surgeons, interventional radiologists and pulmonologists.

lt;br /> Jeffrey A. Bogart, M.D., is the current chair of the Department of Radiation Oncology at Upstate Medical University. Bogart, professor of radiation oncology, joined the SUNY Upstate faculty in 1993. He is currently chair or co-chair of eight Cancer and Leukemia Group B (CALGB)-funded multicenter clinical trials and one National Institutes of Health (NIH) study. He serves on several oversight and advisory committees for the NIH. Bogart, a resident of Jamesville, is an active leader in the CALGB for which he currently serves on its Executive Committee, Board of Directors, and as chair of its Radiation Oncology committee. He is also active in a range of other national organizations in therapeutic radiology and oncology. He is a member of the editorial board of The Journal of Clinical Oncology.

The spectrum of tumor aggressiveness in early stage Cancer.- The spectrum of patients with early cancer.- What is the appropriate evaluation for early stage NSCLC.- How do we assess outcomes in high risk patients.- Definition of high risk.- Which tumors are amenable to a lesion-only approach.- Technical consideration of minimally invasive surgery for stage I NSCLC.- Technical considerations of SBRT treatment planning and delivery.- Technical considerations of Ablative treatments (RFA).- Outcomes of surgical resection (VATS lobe, segment, wedge) in high risk patients.- Outcomes of SBRT in high risk patients.- Outcomes of RFA in high risk patients.- How should high-risk patients with peripheral stage I NSCLC be counseled regarding treatment alternatives (SLR vs SBRT vs RFA)?.- Synchronous primary NSCLC lesions / oligometastatic disease.- Considerations of salvage local therapy in previously treated stage I NSCLC.- Which patients with stage I NSCLC may benefit from systemic therapy.- Is there still a role for fractionated radiotherapy in medically inoperable peripheral early stage NSCLC.- Proton and charged particle therapy in the era of SBRT.

Erscheint lt. Verlag	13.6.2019
Zusatzinfo	Approx. 250 p. 100 illus., 50 illus. in color.
Verlagsort	Cham
Sprache	englisch
Maße	178 x 254 mm
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Pneumologie
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
Schlagworte	Early Stage NSCLC • Lung Cancer • Non-small cell lung cancer • Proton Therapy in Lung Cancer • Radiofrequency ablation • Radiotherapy in Lung Cancer • Stereotactic Body Radiation Therapy • Sublobar resection • Synchronous primary NSCLC lesions
ISBN-10	3-319-08538-7 / 3319085387
ISBN-13	978-3-319-08538-8 / 9783319085388
Zustand	Neuware